Fayez Habach1,2, Jennifer Barry3, Melissa Larsen3, Marne Jamieson4, Amit Singnurkar5, Michael Laflamme6, and Nilesh Ghugre1,2
1Medical Biophysics, University of Toronto, Toronto, ON, Canada, 2Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada, 3Schulich Heart Research Program, Sunnybrook Research Institute, Toronto, ON, Canada, 4Nuclear Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 5Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 6Mcewen Stem Cell Institute, University Health Network, Toronto, ON, Canada
Synopsis
Hybrid PET/MRI is a
promising tool that can characterize both metabolic and structural information and has
been used extensively in the context of MI-related heart failure. We propose a
novel dual-condition protocol that can be used to characterize metabolic state
of cardiac tissue in vivo following MI, under different substrate conditions. Our
results show significant metabolic changes under fasting and glucose loading
conditions, and further longitudinal differences in MI-related metabolic
remodeling within both the infarct zone and surrounding myocardium. This
framework has potential to be used in testing therapeutic efficacy following
MI in both preclinical and clinical contexts.
Introduction
Over the past few decades, the
characterization of myocardial infarction (MI) and the consequent structural
remodeling of the heart has revealed much about the functional consequences
that eventually lead to heart failure.1 Several treatments have held
promise for the recovery of damaged heart tissue, including acellular
biomaterial scaffolds, endogenous therapies, and stem cell based treatments.2 For successful clinical translation, Magnetic Resonance Imaging (MRI) can
elucidate structure, function, and viability, and evaluate treatment efficacy. MRI is
the gold standard for cardiac function and viability assessment and provides
excellent soft tissue contrast for detection of edema and fibrosis with high
spatial resolution.3 In addition, Positron Emission
Tomography (PET) can offer metabolic information, as well as status on inflammatory
processes.4 PET imaging with selective radiotracers is able to
quantify the myocardial metabolic state post-MI. Clinically,
glycolytic suppression is typically used to isolate inflammatory or ischemic
activity. Additionally, glucose loading can provide further information by
inducing metabolite uptake within the myocardium.4 Combining fasting
and glucose loading protocols (dual condition) in one imaging session could
have the advantages of reduced scan time and cost, while also providing better
PET/MRI co-registration. The objective of this work was to develop a hybrid PET/MRI
imaging protocol that will accurately and simultaneously reflect myocardial structure,
function and metabolism using a novel dual-condition protocol, in an
experimental model of MI.Methods
A whole-body
clinical PET/MRI scanner (Siemens mMR) and a validated porcine model5 of MI (90 min LAD occlusion/reperfusion) was utilized. Fasting was induced by a
24 hour fast and injection of a heparin bolus (2000 IU). Glucose loading was
induced by a 30-minute constant dextrose infusion (0.8 mL/min/kg).
Physiological blood glucose measurements in fasted/glucose loaded states were
studied in offline experiments (n=2). Imaging was performed at baseline, 10-,
31-, and 45-days post-MI (n=1). For MRI a CINE sequence was used to assess
anatomy and function and 3D Late Gadolinium Enhancement (LGE) (1x1x2 mm res.) was used
to delineate scar tissue. For PET, a 1-hour dynamic list-mode acquisition (2 mm iso. res.) was
performed concurrently with MRI, immediately following 18FDG
dosing (2.5 mCi) in the fasted state. Next, with a second FDG dose (7.5 mCi), a
1.5-hour acquisition was performed following glucose loading. 3D LGE was co-registered
with 3D 18FDG-PET images for SUV comparison within infarct and
healthy myocardial regions. Manual R.O.I.s were selected within these regions for PET standard uptake value (SUVs) calculations. SUVs were corrected
for the second imaging session by appropriate activity subtraction. Cardiac
gating was used to isolate diastolic phase, and respiratory gating was also
used to minimize respiratory motion. 3D LGE was co-registered with 3D 18FDG-PET
images for SUV comparison within infarct and healthy myocardial regionsResults
Offline physiological
experiments showed changes in blood glucose post heparin (-0.25 ± 0.05 mmol/L)
and post-dextrose infusion (+5.1 ± 0.3 mmol/L), and glucose loading induced almost
6-fold increase in tracer uptake immediately after dextrose infusion (Figure 1A).
Co-registered 3D LGE and 18FDG-PET showed strong spatial correlations
between infarct location and inflammatory cell activity (Figure 2C). Longitudinal
tracking of metabolic activity following induced MI was measured over a period
of 7 weeks and significantly decreased within infarct scar zone (p < 0.01),
while remaining in surrounding infarct adjacent myocardium. (Figure 3)Discussion
A dual-condition 18FDG-PET
protocol shows promise as an in vivo imaging method that accurately measures
metabolic activity under different metabolic states, within the same imaging
session. Combining this with structural information provided by 3D MRI provided
high resolution contrast enhanced hybrid images. This framework has the
potential to accurately characterize MI related therapies and the evolution of
metabolic activity over a long period of time, while also reducing costs and
scanning time significantly for large animal investigations. Developing the PET/MRI
framework also opens the possibility of its widespread use as an in vivo
non-invasive imaging modality for both pre-clinical efficacy testing and
clinical implications for response monitoring in patients suffering from
MI-related heart failure.Acknowledgements
We acknowledge the funding support from Ontario Research Fund, and the University of Toronto’s Medicine by Design initiative which receives funding from the Canada First Research Excellence Fund. We also acknowledge research support from Siemens Healthineers, Canadian Institute for Health Research, and the Heart and Stroke Foundation of Canada.References
- Taegtmeyer, H., Dilsizian, V. Imaging myocardial metabolism and
ischemic memory. Nat. Rev. Cardiol. 5, S42–S48 (2008).
https://doi.org/10.1038/ncpcardio1186
- Hastings, L. C. et al. Drug
and cell delivery for cardiac regeneration. Adv. Drug Deliv. Rev. 84, 85-106
(2015). https://doi.org/10.1016/j.addr.2014.08.006
- Naumova, A. V.,
Modo, M., Moore, A., Murry, C. E., & Frank, J. A. Clinical imaging in
regenerative medicine. Nat. Biotechnol. 32(8), 804–818 (2014).
https://doi.org/10.1038/nbt.29937
- Kunze, K.P., et al. Quantitative cardiovascular magnetic
resonance: extracellular volume, native T1 and 18F-FDG PET/CMR imaging in
patients after revascularized myocardial infarction and association with
markers of myocardial damage and systemic inflammation. J. Cardiovasc. Magn.
Reson. 20, 33 (2018). https://doi.org/10.1186/s12968-018-0454-y
- Romagnuolo, R.,
et al. Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate the
Infarcted Pig Heart but Induce Ventricular Tachyarrhythmias. Stem Cell Rep.
12(5), 967-981 (2019). https://doi.org/10.1016/j.stemcr.2019.04.005